Valcon Medical is proud to announce its new partnership agreement with a well reputed Polish manufacturer of medicinal cannabis
Introduction of medicinal cannabis to the Polish market requires a marketing authorisation for a pharmaceutical raw material to prepare prescription drugs in the form of non-fibrous hemp herbs, extracts, and tinctures.
COPENHAGEN, DENMARK, March 22, 2023 - Valcon Medical, a leading pharmaceutical company, is thrilled to announce its new partnership agreement with a well-respected Polish manufacturer of medicinal cannabis. As part of this collaboration, Valcon Medical has successfully exported the first batches of 060518 Herbal extract (THC), which will be used to formulate pilot batches of standardised cannabis oil.
Introducing medicinal cannabis to the Polish market necessitates a marketing authorisation for a pharmaceutical raw material. This material is used to prep prescription drugs in the form of non-fibrous hemp herbs, extracts, and tinctures. Valcon Medical's partnership always includes a strong collaboration on the regulatory framework, ensuring compliance with national requirements for introducing medicinal cannabis to the market.
Poland has recently made significant strides in the regulation of medical cannabis. In 2017, the Polish government passed a law allowing for the use of cannabis for medical purposes. This law permits patients with certain medical conditions, such as chronic pain, epilepsy, and multiple sclerosis, to access cannabis-based treatments under the supervision of a healthcare professional.
To ensure the safe and responsible distribution of medicinal cannabis, the Polish government has implemented a strict regulatory framework. This framework includes the requirement of a marketing authorisation for pharmaceutical raw materials used to prepare prescription drugs. Valcon Medical, in partnership with its Polish collaboration partners, adheres to these regulations and holds the necessary licenses to handle and manufacture medicinal cannabis products.
The very foundation of the partnership between Valcon Medical and its collaboration partners in Poland is rooted in the following licenses:
- Narcotic license, including handling of group I-N intoxicating substances issued by the Chief Pharmaceutical Inspectorate. This license ensures that Valcon Medical complies with the highest standards when handling medicinal cannabis.
- Manufacturing and Importation Authorisation (MIA), where the manufacturing operation includes raw materials used for preparing medicinal products in the pharmacy according to doctor’s prescription or Pharmacopoeia formula and batch certification
About Valcon Medical
Valcon Medical is a leading pharmaceutical company dedicated to improving the health and well-being of individuals through developing high-quality medicinal products. With a strong focus on research and innovation, Valcon Medical strives to provide effective solutions for a wide range of medical conditions.
Valcon Medical is actively seeking new collaboration partners who share its commitment to improving patient care by dev high-quality medicinal cannabis products. If you are interested in partnering with Valcon Medical, we encourage you to contact us at firstname.lastname@example.org to discuss the possibilities.
You might also be interested in
Valcon Medical Granted Authorisation by The Danish Medicines Agency for Manufacturing Cannabis Bulk Extracts under the Pilot Programme
With the authorisation to manufacture cannabis bulk extracts under the pilot programme, the company will leverage its expertise to manufacture high-quality cannabis bulk extracts, ensuring strict adherence to regulations and guidelines.
Valcon Medical granted authorisation by The Danish Medicines Agency for activities with euphoriant substances
Danish Medicines Agency has granted Valcon Medical the necessary approval to engage in activities related to euphoriant substances marking a significant milestone for and enforces its commitment to providing safe and effective treatments to chronic patients.
The European Pharmacopoeia Commission (EPC) has adopted a new European monograph for Cannabis flower
The European Pharmacopoeia Commission has adopted a new European monograph for Cannabis flower at the latest Commission meeting in June 2023. The monograph describes quality requirements for the raw material Cannabis flower.